Research progress on the role of N6-methyladenosine (m6A) RNA modification in reproductive system diseases

Abstract

Abstract: N6-methyladenosine (m6A) RNA modification is a post-transcriptional modification occurring on the 6th N atom of RNA adenine (A), regulating the structure, stability, splicing, output, translation and decay of mRNA, and thus extensively affecting the life processes of various organisms.This paper summarized the role and mechanism of various m6A methylase in the occurrence and development of reproductive system diseases and breast caner, in order to provide new basis for early diagnosis, treatment and improved prognosis of reproductive system diseases and breast caner.

Key words: N6-methyladenosine(m6A), reproductive system diseases, epigenetics, breast cancer

CLC Number:

R394.3

ZHANG Yan, ZHU Meng-wen, LIU Tong, YANG Sheng, LIANG Ge-yu. Research progress on the role of N6-methyladenosine (m6A) RNA modification in reproductive system diseases[J]. Basic & Clinical Medicine, 2021, 41(9): 1347-1351.

References

[1]Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation[J]. Nucleic Acids Res, 2020,48:3816-3831.
[2]Zhu H, Gan X, Jiang X, et al. ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and Bcl-2[J]. J Exp Clin Cancer Res, 2019,38:163.doi: 10.1186/s13046-019-1159-2.
[3]Ding C, Zou Q, Ding J, et al. Increased N6-methyladenosine causes infertility is associated with FTO expression[J]. J Cell Physiol, 2018,233:7055-7066.
[4]Huang B, Ding C, Zou Q, et al. Cyclophosphamide regulates N6-methyladenosine and m6A RNA enzyme levels in human granulosa cells and in ovaries of a premature ovarian aging mouse model[J]. Front Endocrinol (Lausanne), 2019,10:415.doi: 10.3389/fendo.2019.00415.
[5]Fan Y, Zhang C, Zhu G. Profiling of RNA N6-methyladenosine methylation during follicle selection in chicken ovary[J]. Poult Sci, 2019,98:6117-6124.
[6]Liu L, Liu X, Dong Z, et al. N6-methyladenosine-related genomic targets are altered in breast cancer tissue and associated with poor survival[J]. J Cancer, 2019,10:5447-5459.
[7]Wu L, Wu D, Ning J, et al. Changes of N6-methyladenosine modulators promote breast cancer progression[J]. BMC Cancer, 2019,19:326.doi: 10.1186/s12885-019-5538-z.
[8]Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3[J]. Mol Cancer, 2019,18:46.doi: 10.1186/s12943-019-1004-4.
[9]Wang H, Xu B, Shi J. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2[J]. Gene, 2020,722:144076. doi: 10.1016/j.gene.2019.144076.
[10]Fry NJ, Law BA, Ilkayeva OR, et al. N(6)-methyladenosine contributes to cellular phenotype in a genetically-defined model of breast cancer progression[J]. Oncotarget, 2018,9:31231-31243.
[11]Wang X, Li Z, Kong B, et al. Reduced m(6)A mRNA methylation is correlated with the progression of human cervical cancer[J]. Oncotarget, 2017,8:98918-98930.
[12]Zou D, Dong L, Li C, et al. The m(6)A eraser FTO facilitates proliferation and migration of human cervical cancer cells[J]. Cancer Cell Int, 2019,19:321.doi: 10.1186/s12935-019-1045-1.
[13]Zhou S, Bai ZL, Xia D, et al. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcino-ma (CSCC) by targeting beta-catenin through mRNA demethylation[J]. Mol Carcinog, 2018,57:590-597.
[14]Liu J, Eckert MA, Harada BT, et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer[J]. Nat Cell Biol, 2018,20:1074-1083.
[15]Li XC, Jin F, Wang BY, et al. The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of CYR61 mRNA[J]. Theranostics, 2019,9:3853-3865.
[16]Ivanova I, Much C, Di Giacomo M, et al. The RNA m(6)A reader YTHDF2 is essential for the post-transcriptional regulation of the maternal transcriptome and oocyte competence[J]. Molecular cell, 2017,67:1059-1067.
[17]Sui X, Hu Y, Ren C, et al. METTL3-mediated m(6)A is required for murine oocyte maturation and maternal-to-zygotic transition[J]. Cell Cycle, 2020,19:1-14.
[18]Cai J, Yang F, Zhan H, et al. RNA m(6)A methyltransferase METTL3 promotes the growth of prostate cancer by regulating Hedgehog pathway[J]. Onco Targets Ther, 2019,12:9143-9152.
[19]Lobo J, Costa AL, Cantante M, et al. m(6)A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance[J]. J Transl Med, 2019,17:79.doi: 10.1186/s12967-019-1837-z.
[20]Chen Y, Wang J, Xu D, et al. m(6)A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells[J]. Autophagy, 2021,17:457-475.
[21]Zhao TX, Wang JK, Shen LJ, et al. Increased m6A RNA modification is related to the inhibition of the Nrf2-mediated antioxidant response in di-(2-ethylhexyl) phthalate-induced prepubertal testicular injury[J]. Environ Pollut, 2020,259:113911.doi: 10.1016/j.envpol.2020.113911.
[22]Yuan JT, Gatti DM, Philip VM, et al. Genome-wide association for testis weight in the diversity outbred mouse population[J]. Mamm Genome, 2018,29:310-324.
[23]Huang T, Liu Z, Zheng Y, et al. YTHDF2 promotes spermagonial adhesion through modulating MMPs decay via m(6)A/mRNA pathway[J]. Cell Death Dis, 2020,11:37.doi: 10.1038/s41419-020-2235-4.
[24]Tang C, Klukovich R, Peng H, et al. ALKBH5-depen-dent m6A demethylation controls splicing and stability of long 3′-UTR mRNAs in male germ cells[J]. Proc Natl Acad Sci U S A, 2018,115:325-333.
[25]Yang Y, Huang W, Huang J T, et al. Increased N6-methyladenosine in human sperm RNA as a risk factor for asthenozoospermia[J]. Sci Rep, 2016,6:24345.doi: 10.1038/srep24345.